Menu Close

Gantenerumab does not slow clinical decline in early Alzheimer disease, research finds

The use of gantenerumab leads to lower amyloid plaque burden at 116 weeks, but is not associated with slower clinical decline among patients with early Alzheimer disease, according to a study published in the Nov. 16 issue of the New England Journal of Medicine.